Coronavirus (COVID-19) is raising valid concerns among our communities and one such concern is around the possibility of interrupted supply chains for medications for people living with HIV and PrEP users.
Following extensive consultation with pharmaceutical companies, the Therapeutic Goods Administration (TGA), and the Pharmaceutical Benefits Advisory Committee (PBAC) the key message is that COVID-19 poses no threat to the availability of HIV medications for Australian consumers.
To help you learn more about COVID-19 NAPWHA has co-produced with Australian Federation of AIDS Organisations (AFAO) and Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine an updated fact sheet released on 9 March 2020 (this is an updated version of the Factsheet published on 5 February 2020).
